drugset
drugset / Trial / NCT02633007

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

NCT02633007 ↗

Phase 1 Completed 25 enrolled Acorda Therapeutics
RandomizedCrossoverDouble-blindTreatment

Summary

This study is a double-blind, randomized, placebo-controlled, 2-period, crossover study to evaluate safety and PK of 3 doses of CVT 301 levodopa (l-dopa) in adults with asthma.

Timeline

Start
2015-12
Primary completion
2016-03
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Levodopa Small molecule — Inhaled
Background Carbidopa Unknown — Oral

Indications

asthma